Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19

 Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19

Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19

Shots:

  • The P-III COV-BARRIER study evaluating Baricitinib (4 mg, qd) + SoC (corticosteroids, antimalarials, antivirals, azithromycin) vs PBO + SoC in 1525 patients hospitalized with COVID-19. The patients treated with baricitinib in addition to SoC includes 79% receiving corticosteroids and 19% receiving remdesivir, with some receiving both
  • The trial did not meet 1EPs i.e. showed a 38% reduction in mortality by Day 28, non-invasive mechanical ventilation at baseline (17.5% vs 29.4%)
  • Lilly plans to publish the data in a peer-reviewed journal in the coming mos. and share the data with regulatory authorities in the US, EU, and other geographies

Click here to­ read full press release/ article | Ref: Incyte | Image: Wikipedia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post